广州维力医疗器械股份有限公司 董事会提名委员会实施细则 广州维力医疗器械股份有限公司 董事会提名委员会实施细则 （2025 年 7 月修订） 第一章 总则 第一条 为规范广州维力医疗器械股份有限公司（以下简称"公司"）领导人员的 产生，优化董事会组成，完善公司治理结构，根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司 治理准则》《上市公司独立董事管理办法》《上海证券交易所股票上市规则》《上海证 券交易所上市公司自律监管指引第 1 号——规范运作》《广州维力医疗器械股份有限 公司章程》（以下简称"《公司章程》"）及其他有关规定，公司特设立董事会提名委员 会，并制订本实施细则。 第二条 董事会提名委员会是董事会按照股东会决议设立的专门工作机构，主要 负责对公司董事和高级管理人员的人选、选择标准和程序进行选择并提出建议。 第二章 人员组成 第三条 提名委员会成员由三名董事组成，独立董事应当过半数。 第四条 提名委员会委员由董事长、二分之一以上独立董事或者全体董事的三分 之一提名，并由董事会选举产生。 第五条 提名委员会设主任委员（召集人）一名， ...

重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第一次临时股东大会 广州维力医疗器械股份有限公司 证券代码：603309 证券简称：维力医疗 公告编号：2025-049 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 网络投票起止时间：自2025 年 8 月 15 日 至2025 年 8 月 15 日 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 8 月 15 日 14 点 00 分 召开地点：广州市番禺区化龙镇国贸大道南 47 号公司一号楼二楼会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 股东大会召开日期：2025年8月15日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大 ...

Group 1 - The core viewpoint of the article highlights the current financial performance and market position of Weili Medical, indicating a low PE ratio compared to the industry average [1][3] - As of July 16, Weili Medical's closing price was 13.44 yuan, with a PE ratio of 17.26, marking a new low in 151 days, and a total market capitalization of 3.936 billion yuan [1] - The average PE ratio for the medical device industry is 51.87, with a median of 37.48, positioning Weili Medical at the 40th rank within the industry [1][3] Group 2 - Weili Medical specializes in the research, production, and sales of medical devices in various fields, including anesthesia, urology, and respiratory care, with products widely used in surgeries and emergency care [2] - The latest quarterly report for Q1 2025 shows Weili Medical achieved a revenue of 348 million yuan, representing a year-on-year increase of 12.60%, and a net profit of 58.92 million yuan, up 17.25%, with a gross profit margin of 44.78% [2]

Summary of the Conference Call Company Overview - The conference call is regarding Weili Medical, a leading company in the medical device industry in China, with a focus on anesthesia and other medical fields [1][2]. Key Points and Arguments - **Market Position**: Weili Medical has established a strong market presence, holding a leading position in the anesthesia and guiding materials sectors, with increasing market share in other product areas [2]. - **Product Development**: The company has developed over 500 medical device registrations globally and has established partnerships with over 100 countries. Continuous investment in R&D has led to the launch of multiple innovative products that have gained recognition from clinical professionals [2]. - **Financial Performance**: - In 2020, Weili Medical reported a revenue of 1.509 billion yuan, an increase of 8.76% year-on-year, and a net profit of 219 million yuan, up 13.98% year-on-year [3]. - For Q1 2025, the company achieved a revenue of 348 million yuan, a 12.6% increase year-on-year, and a net profit of approximately 58.92 million yuan, reflecting a growth of 17.25% [5]. - **Future Outlook**: The company anticipates challenges and opportunities in the evolving political and economic landscape, aiming for sustainable growth and improved investor returns through strategic market focus and product innovation [4]. Additional Important Information - **Sales Breakdown**: - The sales revenue for 2024 is projected to be approximately 1.479 billion yuan, with a year-on-year growth of 8.35%. The export revenue is expected to reach around 797 million yuan, showing a significant increase of 23.74% [6]. - The company’s product lines show varied performance, with anesthesia products generating 470 million yuan in 2020, a 2% increase, while the surgical line reached 210 million yuan, up 6.2% [8]. - **Challenges in Specific Segments**: The respiratory product line has faced a decline due to lower disease incidence compared to the previous year, impacting sales [8]. - **Cost Management**: The company has maintained a cash dividend ratio below 30% since its IPO in 2015, with a cumulative cash dividend of 6.3% from 2015 to 2020 [3]. This summary encapsulates the essential insights from the conference call, highlighting Weili Medical's market position, financial performance, and strategic outlook.

Core Points - Vili Medical (603309) closed at 12.93 yuan on July 11, 2025, up 0.7% from the previous week [1] - The company's total market capitalization is 3.787 billion yuan, ranking 90th out of 126 in the medical device sector and 3795th out of 5149 in the A-share market [1] Company Announcements - Vili Medical's wholly-owned subsidiary, Hainan Vili, received a Class II medical device registration certificate for a single-use hydrophilic coated visual nasogastric tube [1] - The product is designed for delivering nutrients, gastric decompression, and flushing, consisting of a feeding connector, gastric tube, and a bullet head with a camera [1] - The registration certificate was issued on July 7, 2025, and is valid until July 6, 2030 [1] - Currently, there are no similar products available in the domestic market, which may enhance the subsidiary's product variety and market competitiveness [1] - Although the registration is expected to positively impact the company's operations, the product has not yet been marketed, and its short-term effect on financial performance is minimal [1] - The actual sales performance will depend on future marketing efforts, and the specific impact on the company's future financial results remains uncertain [1]

Investment Rating - The report maintains an optimistic outlook on the pharmaceutical industry, particularly for 2025, suggesting a potential for diverse investment opportunities as the sector recovers from low valuations and public fund allocations [10]. Core Insights - The pharmaceutical sector is currently experiencing low valuations, with public funds under-allocating to this area. The report anticipates a recovery driven by macroeconomic factors and significant product launches [10]. - The report emphasizes a shift in the innovative drug sector from quantity to quality, highlighting the importance of differentiated products and international expansion for profitability [10]. - The medical device sector is seeing a rebound in bidding volumes, particularly in imaging equipment, and is expected to benefit from domestic product upgrades and international market expansion [10]. - The report identifies a growing trend in the CXO and life sciences services sector, with expectations for increased investment and a recovery in demand [10]. - The traditional Chinese medicine sector is projected to benefit from policy changes and market dynamics, with specific companies recommended for investment based on their unique product offerings and market positions [12]. Summary by Sections Market Review - The report notes a 1.80% increase in the CITIC Pharmaceutical Index, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 sectors [7]. - The top-performing stocks include Frontline Bio-U, MediWest, and Lianhuan Pharmaceutical, while the worst performers include ST Weiming and Innovent Biologics [7]. Overall Perspective and Investment Themes - The report suggests that the pharmaceutical industry is poised for growth, with a focus on innovative drugs, medical devices, and traditional Chinese medicine. Specific companies are highlighted for their potential in these areas [10][12]. - The report also discusses the implications of policy changes and market trends for the pharmaceutical and medical device sectors, indicating a favorable environment for investment [10][12]. Company-Specific Insights - Companies like Baiyi, Xinda, and Kangfang are highlighted for their innovative drug pipelines and potential for growth in the coming years [10][12]. - The report provides detailed insights into the clinical progress of various drugs across different companies, indicating a robust pipeline that could drive future revenue [13][20][24][30][35][38].

证券代码：603309 证券简称：维力医疗 公告编号：2025-043 生产地址：海口国家高新区美安生态科技新城美安三街 39 号 广州维力医疗器械股份有限公司 关于全资子公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州维力医疗器械股份有限公司（以下简称"公司"）全资子公司海南维力医疗 科技开发有限公司（以下简称"海南维力"）于近日收到海南省药品监督管理局颁发 的《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 注册证编号：琼械注准 20252140055 注册人名称：海南维力医疗科技开发有限公司 注册人住所：海口国家高新区美安生态科技新城美安三街 39 号 截至目前，海南维力上述产品尚未进行销售，上述医疗器械注册证的取得，短 期内对海南维力及公司的经营业绩影响较小。 四、风险提示 产品名称：一次性使用亲水涂层可视鼻胃肠管 结构及组成：一次性使用亲水涂层可视鼻胃肠管（喂养型）由喂养接头、胃肠 主管、带摄像头的子弹头、营养液出口、信号接口、导丝、喂养转换接头 ...

Core Viewpoint - The article highlights the success of Weili Medical Technology Co., Ltd. in leveraging the "processing value-added 30% duty-free policy" in Hainan Free Trade Port, which has significantly boosted its production and market competitiveness [2][4][5]. Company Overview - Weili Medical primarily produces disposable latex catheters, with a production capacity of 300,000 units per day, serving over 3,000 hospitals domestically and exporting to 110 countries and regions [4][8]. - The company has seen its annual output value approach 200 million yuan, with employee numbers growing from fewer than 10 to over 600 [8]. Policy Impact - The "processing value-added 30% duty-free policy" allows companies to enjoy tax exemptions on goods that undergo significant processing in Hainan, effectively reducing procurement costs and enhancing product competitiveness [4][5]. - Since the implementation of this policy, Weili Medical has saved over 3 million yuan in duties [7]. Market Position - Weili Medical has established itself as a significant supplier of medical catheters globally, with a market share ranking among the top in the industry [4][8]. - The company is experiencing strong demand, with orders extending two months ahead, indicating a robust market position [4]. Future Prospects - The company plans to increase investment in new product development and aims to maintain a growth rate of 30%, contributing to the development of the medical device industry in Hainan [8][10]. - Hainan's favorable business environment is seen as a catalyst for innovation and growth within the company [8].

Group 1 - The core viewpoint of the article highlights that Rui Feng Hui Bang, a well-known private equity firm, has conducted research on a listed company, Weili Medical, focusing on its strategies to address domestic medical consumables procurement and the growing demand for overseas production capacity [1] - Weili Medical is actively establishing a factory in Mexico starting in 2024 to meet production needs and is also preparing a second overseas production base in Indonesia, which is expected to complete its first phase of construction and production by the end of this year [1] - The company is developing key products in its anesthesia line, nursing line, and urology field, aiming to launch these products quickly to better meet clinical needs while expanding its product range through technology transformation [1]

Summary of Key Points Core Viewpoint - Vili Medical (603309) has shown a positive stock performance with a closing price of 12.48 CNY as of June 27, 2025, reflecting a 3.23% increase from the previous week [1]. Company Performance - The stock reached a weekly high of 12.62 CNY on June 25 and a low of 12.00 CNY on June 23 [1]. - The current total market capitalization of Vili Medical is 3.655 billion CNY, ranking 89th out of 126 in the medical device sector and 3822nd out of 5151 in the overall A-share market [1]. Recent Developments - Vili Medical has announced its participation in establishing the Vizh Medical Navigation (Suzhou) Medical Industry Investment Partnership, committing a capital contribution of 37.5 million CNY [1]. - The partnership aims to raise a total of 150 million CNY, with Vili Medical's contribution accounting for 25% of the total [1]. - The partnership has completed its business registration and obtained a business license from the Suzhou Industrial Park Administrative Approval Bureau [1].